Switching from originator recombinant growth hormone...

Growth Hormone & IGF Research 2021 / 02 Vol. 56

Switching from originator recombinant growth hormone (Genotropin™) to biosimilar (CRISCY™): Results from a 6-month, multicentric, non-inferiority, extension trial.

Czepielewski, M.A., Garret, Q., Vencio, S.A.C., Rassi, N., Faria, M.S., Senn, C.C.P., Bronstein, M.D., Cerqueira, M.J.A.G., Neves, A.C.L., Spinola-Castro, A.M., Cunha, M.P.R., Leite, N.R., Wassermann,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
56
Journal:
Growth Hormone & IGF Research
DOI:
10.1016/j.ghir.2020.101372
Date:
February, 2021
File:
PDF, 173 KB
2021
Conversion to is in progress
Conversion to is failed